The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects

Vaccines have proven effective in the treatment and prevention of numerous diseases. However, traditional attenuated and inactivated vaccines suffer from certain drawbacks such as complex preparation, limited efficacy, potential risks and others. These limitations restrict their widespread use, espe...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 15; p. 1332939
Main Authors Lu, Bowen, Lim, Jing Ming, Yu, Boyue, Song, Siyuan, Neeli, Praveen, Sobhani, Navid, K, Pavithra, Bonam, Srinivasa Reddy, Kurapati, Rajendra, Zheng, Junnian, Chai, Dafei
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 01.02.2024
Subjects
Online AccessGet full text
ISSN1664-3224
1664-3224
DOI10.3389/fimmu.2024.1332939

Cover

More Information
Summary:Vaccines have proven effective in the treatment and prevention of numerous diseases. However, traditional attenuated and inactivated vaccines suffer from certain drawbacks such as complex preparation, limited efficacy, potential risks and others. These limitations restrict their widespread use, especially in the face of an increasingly diverse range of diseases. With the ongoing advancements in genetic engineering vaccines, DNA vaccines have emerged as a highly promising approach in the treatment of both genetic diseases and acquired diseases. While several DNA vaccines have demonstrated substantial success in animal models of diseases, certain challenges need to be addressed before application in human subjects. The primary obstacle lies in the absence of an optimal delivery system, which significantly hampers the immunogenicity of DNA vaccines. We conduct a comprehensive analysis of the current status and limitations of DNA vaccines by focusing on both viral and non-viral DNA delivery systems, as they play crucial roles in the exploration of novel DNA vaccines. We provide an evaluation of their strengths and weaknesses based on our critical assessment. Additionally, the review summarizes the most recent advancements and breakthroughs in pre-clinical and clinical studies, highlighting the need for further clinical trials in this rapidly evolving field.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Kalpit A. Vora, Merck, United States
Reviewed by: Kai Zhao, Taizhou University, China
These authors have contributed equally to this work
Thavasimuthu - Citarasu, Manonmaniam Sundaranar University, India
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2024.1332939